Health Rounds newsletter excerpt has been corrected to indicate in the headline and the first item of the story that Sanofi ...

Ataciguat, a new drug being studied for aortic valve stenosis, shows promise in slowing disease progression and reducing the ...

Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally. Researchers are exploring the use of a new drug called ataciguat to manage ...

More than 60,000 people die from heart valve disease (HVD) in the U.S. each year, according to the American Heart Association ...

Aortic stenosis is fairly uncommon among young people, though not absent. In younger folks, the disease is typically caused by a congenital heart condition. As we age, calcium deposits can build up ...

An experimental drug, ataciguat, initially created by Sanofi and further developed by the Mayo Clinic, has significantly ...

Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally.

Heart Valve Disease Awareness Day, observed annually on February 22, is dedicated to educating the public about the risks, ...

Sanofi's experimental drug ataciguat has shown promise in reducing the progression of aortic valve stenosis in clinical trials, potentially delaying the need for surgical valve replacement. With ...

If validated prospectively, the findings could be ‘transformative’ for patients with no current medical options.

An experimental drug being developed by Sanofi significantly curbed progression of aortic valve stenosis, a common heart ...

Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally.